5 Key Takeaways

• 1

  A new CRISPR-based method enables in vivo production of CAR T cells, addressing manufacturing bottlenecks in cell therapy.

• 2

  The approach uses a two-vector system that inserts therapeutic genes into a T cell-specific genomic site.

• 3

  In humanized mouse models, the system generated CAR T cells that reached therapeutic levels and induced B cell depletion.

• 4

  Engineered delivery components enhance specificity and efficiency, targeting T cells and improving uptake.

• 5

  If successful in humans, this method could reduce costs and increase access to CAR T therapies by eliminating ex vivo processes.